Amicus Therapeutics, Inc.
General ticker "FOLD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.0B
Amicus Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -14.7%.
Estimated limits based on current volatility of 1.9%: low 9.52$, high 9.89$
Factors to consider:
- US accounted for 36.8% of revenue in the fiscal year ended 2023-12-31
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [10.56$, 20.18$]
- 2024-12-30 to 2025-12-30 estimated range: [13.52$, 24.51$]
Financial Metrics affecting the FOLD estimates:
- Negative: Non-GAAP EPS, $ of -0.51 <= 0.10
- Negative: Operating profit margin, % of -16.29 <= 1.03
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Interest expense per share, $ of 0.17 <= 0.74
- Negative: Operating cash flow per share per price, % of -1.93 <= 2.35
- Negative: Inventory ratio change, % of 7.64 > 1.08
Short-term FOLD quotes
Long-term FOLD plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $299.00MM | $328.15MM | $396.77MM |
| Operating Expenses | $505.43MM | $540.27MM | $473.98MM |
| Operating Income | $-206.43MM | $-212.12MM | $-77.21MM |
| Non-Operating Income | $-35.12MM | $-29.92MM | $-72.89MM |
| Interest Expense | $32.47MM | $37.12MM | $50.15MM |
| R&D Expense | $272.05MM | $276.68MM | $152.38MM |
| Income(Loss) | $-241.55MM | $-242.04MM | $-150.10MM |
| Taxes | $8.91MM | $-5.47MM | $1.48MM |
| Profit(Loss) | $-250.46MM | $-236.57MM | $-151.58MM |
| Stockholders Equity | $307.37MM | $123.05MM | $160.17MM |
| Inventory | $26.82MM | $23.82MM | $59.70MM |
| Assets | $905.14MM | $724.17MM | $777.88MM |
| Operating Cash Flow | $-202.49MM | $-166.57MM | $-69.09MM |
| Capital expenditure | $3.88MM | $3.77MM | $7.44MM |
| Investing Cash Flow | $78.76MM | $92.32MM | $98.06MM |
| Financing Cash Flow | $212.07MM | $-7.46MM | $61.68MM |
| Earnings Per Share* | $-0.92 | $-0.82 | $-0.51 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.